We Stand in Solidarity Against Racism
The Department of Bioengineering stands in solidarity with our students, staff and faculty against social injustice and acts of racism. We are shocked and saddened by the recent, brutal deaths of George Floyd, Ahmaud Arbery, Breonna Taylor, Nina Pop, and others. Like many members of our community, we are frustrated that these deaths are only the most recent manifestations of long-standing racial inequality in this country.
The Department supports the call to action made by the Bourns College of Engineering.
• We acknowledge that systemic racism permeates and poisons all levels of academia.
• We affirm that the Department has zero tolerance for racism, institutional bias or acts of violence against Black members of our community.
• We are committed to supporting Black students and combating the bias and inequity they face.
• We are committed to critically examining our recruitment and retention efforts to better support Black students, faculty and staff.
We would also like to take this moment to recognize the essential contributions made every day by Black students, faculty and staff. They are part of the Bioengineering family, and the department would not be as strong today without their efforts.
Colloquium Speaker: Nathan Lewis, PhD, Dept. of Bioengineering and Pediatrics, UCSD
Title: Coaxing better therapeutic production through mammalian systems and synthetic biology
Abstract: Over the past years, there has surge in complex therapeutics, including recombinant protein, gene, and cell therapies. However, the manufacturing of these therapeutics necessitates the engineering of complex traits into mammalian cells. In particular, the production of these require substantial resources from cell metabolism and the secretory pathway for drug production or cell type specification and differentiation. Through the use of network reconstruction approaches and protein interaction assays, we are mapping out the mammalian metabolic and secretory pathways, and using these to engineer improved therapeutic production in mammalian cells. I will describe some of these efforts wherein we have deployed graph-based and machine learning approaches to identify key determinants of protein secretion in Chinese hamster ovary (CHO) cells. We have further deployed constraint-based modeling to quantify the bioenergetic demands for the synthesis and secretion of these proteins. Finally, we deployed these models to engineer CHO cells for enhanced secretion of high-value biologic drugs. Thus, through the use of systems and synthetic biology techniques, we are now more able to study and engineer the mammalian secretory pathway and metabolism for systems biotechnology.
Bio: Dr. Lewis is an Associate Professor of Pediatrics and Bioengineering at the University of California, San Diego. He received his training in biochemistry at Brigham Young University, bioengineering at UC San Diego, and genome editing at the Wyss Institute at Harvard Medical School, where he focused on omics and big data analysis using systems biology modeling techniques. Dr. Lewis' lab now focuses on the use of systems biology techniques to study pediatric disorders and to engineer better therapeutics for complex diseases. In particular, he has led efforts to develop systems biology models of mammalian metabolism and the secretory pathway. His group is utilizing these resources to study protein synthesis and secretion in mammalian cells to engineer desired traits into recombinant protein producing cells.